Recurrent neutropenia due to dopamine agonists in a patient with microprolactinoma.

OBJECTIVE: The objective of our case report is to increase the awareness of neutropenia as a rare but potentially serious adverse outcome of commonly used dopamine agonists for the treatment of prolactinomas. METHODS: This report reviews the clinical history, diagnosis, investigations, and drug treatment of our patient. RESULTS: Neutropenia was recurrent after changing to various different dopamine agonists necessitating surgical treatment of a prolactinoma. CONCLUSION: This case serves a reminder of this adverse drug reaction. Considering the significant impact and potentially a life threatening outcome, we advocate routine monitoring of full blood count prior to and during the treatment with dopamine agonists.